MXPA04002709A - Derivados articonvulsivos utiles para el tratamiento del sindrome de extremidades inquietas y trastorno periodico del movimiento de extremidades. - Google Patents

Derivados articonvulsivos utiles para el tratamiento del sindrome de extremidades inquietas y trastorno periodico del movimiento de extremidades.

Info

Publication number
MXPA04002709A
MXPA04002709A MXPA04002709A MXPA04002709A MXPA04002709A MX PA04002709 A MXPA04002709 A MX PA04002709A MX PA04002709 A MXPA04002709 A MX PA04002709A MX PA04002709 A MXPA04002709 A MX PA04002709A MX PA04002709 A MXPA04002709 A MX PA04002709A
Authority
MX
Mexico
Prior art keywords
restless
syndrome
formula
topiramate
alkyl
Prior art date
Application number
MXPA04002709A
Other languages
English (en)
Spanish (es)
Inventor
S Abuzzahab Faruk
Original Assignee
Johnson & Johnson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson filed Critical Johnson & Johnson
Publication of MXPA04002709A publication Critical patent/MXPA04002709A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MXPA04002709A 2001-09-24 2002-09-23 Derivados articonvulsivos utiles para el tratamiento del sindrome de extremidades inquietas y trastorno periodico del movimiento de extremidades. MXPA04002709A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32444001P 2001-09-24 2001-09-24
US10/252,814 US20030092759A1 (en) 2001-09-24 2002-09-23 Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
PCT/US2002/030194 WO2003026676A1 (en) 2001-09-24 2002-09-23 Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder

Publications (1)

Publication Number Publication Date
MXPA04002709A true MXPA04002709A (es) 2005-06-06

Family

ID=23263595

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002709A MXPA04002709A (es) 2001-09-24 2002-09-23 Derivados articonvulsivos utiles para el tratamiento del sindrome de extremidades inquietas y trastorno periodico del movimiento de extremidades.

Country Status (8)

Country Link
US (1) US20030092759A1 (https=)
EP (1) EP1429787A1 (https=)
JP (1) JP2005512965A (https=)
AU (1) AU2002336765B2 (https=)
CA (1) CA2461539A1 (https=)
MX (1) MXPA04002709A (https=)
NZ (1) NZ531871A (https=)
WO (1) WO2003026676A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1041987B1 (en) 1997-12-22 2006-04-19 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and naltrexone
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
HUE032656T2 (en) * 2002-04-05 2017-10-30 Euro Celtique Sa Pharmaceutical composition containing oxicodone and naloxone
US20040115263A1 (en) * 2002-08-26 2004-06-17 Robertson David W. Use of bupropion for treating restless legs syndrome
AU2004274002B2 (en) 2003-09-17 2011-04-28 Arbor Pharmaceuticals, Llc Treating or preventing restless legs syndrome using prodrugs of GABA analogs
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
GEP20105052B (en) * 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
EP2317991B1 (en) * 2008-07-07 2017-05-03 Euro-Celtique S.A. Use of opioid antagonists for treating urinary retention
WO2010036977A2 (en) * 2008-09-25 2010-04-01 New England Medical Center Hospitals, Inc. Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
SG174286A1 (en) 2009-03-10 2011-10-28 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US8690933B2 (en) * 2009-08-31 2014-04-08 Brigham Young University System and method for treating symptoms of restless legs syndrome
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0008791A (pt) * 1999-02-17 2005-04-05 Ortho Mcneil Pharm Inc Derivados anticonvulsivos, úteis no tratamento de tremor essencial
WO2000061138A1 (en) * 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders
HUP0203198A3 (en) * 1999-08-20 2005-07-28 Ortho Mcneil Pharm Inc Pharmaceutical composition comprising a tramadol material and an anticonvulsant drug, process for its preparation and its use
SE0000601D0 (sv) * 2000-02-24 2000-02-24 Jan Hedner Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet

Also Published As

Publication number Publication date
JP2005512965A (ja) 2005-05-12
EP1429787A1 (en) 2004-06-23
AU2002336765B2 (en) 2007-12-20
US20030092759A1 (en) 2003-05-15
NZ531871A (en) 2006-09-29
WO2003026676A1 (en) 2003-04-03
CA2461539A1 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
AU2002336765B2 (en) Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
AU2002336765A1 (en) Anticonvulsant derivatives useful for the treatment of restless limb syndrome and periodic limb movement disorder
US6627653B2 (en) Anticonvulsant derivatives useful for the treatment of depression
US20060122127A1 (en) Methods for reducing the side effects associated with mirtzapine treatment
WO2006053186A2 (en) Method for treatment of movement disorders
PT1691811E (pt) Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
EA002554B1 (ru) Применение кабэрголина при лечении синдрома усталых ног
WO2022261263A1 (en) Methods of treating neuropsychiatric disorders
CA2445528A1 (en) Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
US12485100B2 (en) Treatment of menstrual cycle-induced symptoms
US20100168053A1 (en) Oral delivery system for methylcobalamin to treat disorders
EP4322930A1 (en) Combination of a norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea
Avidan Parasomnias and movement disorders of sleep
WO2010036977A2 (en) Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
JP2007523052A (ja) 鬱病の処置のための蘇生薬モダフィニルおよび抗鬱薬の組み合わせ
CA3186900A1 (en) Compositions and methods for treating psychiatric disorders or symptoms thereof
US20120225916A1 (en) Compositions and Methods to Improve Treatment of Medical Conditions Using D-Cycloserine
MXPA04004380A (es) Tratamiento y prevencion de parestesia que comprende co-terapia con derivados anticonvulsivos y potasio.
EP2891491A1 (en) Use of (r)-phenylpiracetam for the treatment of sleep disorders
JP7185260B2 (ja) 悪夢障害の治療用医薬組成物
Krasuski Dr. Jack’s MedQuik Guide
EA049139B1 (ru) Лечение симптомов, вызванных менструальным циклом
KR20210135834A (ko) 헤스페리딘을 유효성분으로 함유하는 외상 후 스트레스장애 예방 또는 치료용 조성물
JPWO2014163152A1 (ja) ノンレム睡眠促進剤、深睡眠促進剤および自然睡眠誘発剤

Legal Events

Date Code Title Description
FA Abandonment or withdrawal